FibroNox
Biotechnology Research • • 1-10 Employees
Company overview
| Headquarters | XX |
| Website | |
| NAICS | 541714 |
| Founded | 2023 |
| Employees | 1-10 |
Key Contact at FibroNox
Joseph Patti
President & Chief Executive Officer, Executive Director
FibroNox Email Formats
FibroNox uses 1 email format. The most common is {first initial}{last name} (e.g., jdoe@fibronox.com), used 100% of the time.
| Format | Example | Percentage |
|---|---|---|
{first initial}{last name} | jdoe@fibronox.com | 100% |
About FibroNox
FibroNox is focused on developing patented first-in-class therapeutics to treat and reverse life-threatening fibrotic diseases. FibroNox has pioneered the development of selective Nox4 inhibitors and Nrf2 activators that have shown robust protection from fibrosis development and promoted the reversal of age-associated established fibrosis. FibroNox’s initial focus is treating idiopathic pulmonary fibrosis and fibrosis in Duchenne muscular dystrophy. FibroNox’s therapeutics offer the opportunity to reverse age-associated established fibrosis, representing the holy grail for more effective strategies to treat fibrotic diseases.
FibroNox revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Employees by Department
FibroNox has 1 employees across 1 departments.
Departments
Number of employees
Funding Data
FibroNox has never raised funding before.
United Arab Emirates
Italy
Latvia
United KingdomFrequently asked questions
4.8
40,000 users
